APYX Stock Overview
Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Apyx Medical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.50 |
| 52 Week High | US$7.97 |
| 52 Week Low | US$1.21 |
| Beta | 1.09 |
| 1 Month Change | 5.63% |
| 3 Month Change | -40.48% |
| 1 Year Change | -72.01% |
| 3 Year Change | -84.63% |
| 5 Year Change | -74.92% |
| Change since IPO | -54.29% |
Recent News & Updates
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Apr 18
Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Mar 26Recent updates
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Apr 18Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Mar 26Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)
Feb 16Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Sep 14Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?
Jun 07Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically
Mar 21Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation
Dec 14We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate
Aug 30Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M
Aug 11Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin
Jul 18Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth
May 26Are Investors Undervaluing Apyx Medical Corporation (NASDAQ:APYX) By 42%?
Mar 15We Think Apyx Medical (NASDAQ:APYX) Can Easily Afford To Drive Business Growth
Jan 08Shareholder Returns
| APYX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.4% | 1.2% | 2.7% |
| 1Y | -72.0% | -0.05% | 26.0% |
Return vs Industry: APYX underperformed the US Medical Equipment industry which returned -0.1% over the past year.
Return vs Market: APYX underperformed the US Market which returned 26% over the past year.
Price Volatility
| APYX volatility | |
|---|---|
| APYX Average Weekly Movement | 16.0% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APYX's share price has been volatile over the past 3 months.
Volatility Over Time: APYX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 252 | Charlie Goodwin | apyxmedical.com |
Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.
Apyx Medical Corporation Fundamentals Summary
| APYX fundamental statistics | |
|---|---|
| Market cap | US$57.51m |
| Earnings (TTM) | -US$22.81m |
| Revenue (TTM) | US$50.45m |
1.0x
P/S Ratio-2.3x
P/E RatioIs APYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APYX income statement (TTM) | |
|---|---|
| Revenue | US$50.45m |
| Cost of Revenue | US$18.32m |
| Gross Profit | US$32.14m |
| Other Expenses | US$54.94m |
| Earnings | -US$22.81m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 63.70% |
| Net Profit Margin | -45.20% |
| Debt/Equity Ratio | 163.3% |
How did APYX perform over the long term?
See historical performance and comparison